• 1
    Palella FJJr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
  • 2
    International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults J Natl Cancer Inst 2000; 92: 1823-1830.
  • 3
    Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425-432.
  • 4
    Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20: 1645-1654.
  • 5
    Silverberg MJ, Abrams DI. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol 2007; 19: 446-451.
  • 6
    Pantanowitz L, Schlecht HP, Dezube BJ. The growing problem of non-AIDS-defining malignancies in HIV. Curr Opin Oncol 2006; 18: 469-478.
  • 7
    Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27: 884-890.
  • 8
    Crum- Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 2009; 23: 41-50.
  • 9
    Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725-1730.
  • 10
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
  • 11
    Engels EA. Human immunodeficiency virus infection, aging, and cancer. J Clin Epidemiol 2001; 54( suppl 1): S29-S34.
  • 12
    Grulich AE. Living longer with HIV: what does it mean for cancer risk? Curr Opin HIV AIDS 2009; 4: 1-2.
  • 13
    Long JL, Engels EA, Moore RD, Gebo KA. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 2008; 22: 489-496.
  • 14
    Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 2007; 165: 1143-1153.
  • 15
    Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987; 126: 310-318.
  • 16
    Silvestre AJ, Hylton JB, Johnson LM, et al. Recruiting minority men who have sex with men for HIV research: results from a 4-city campaign. Am J Public Health 2006; 96: 1020-1027.
  • 17
    Ferlay J, Burkhard C, Whelan S, Parkin DM. Check and Conversion Programs for Cancer Registries (IARC/IACR Tools for Cancer Registries). IARC Technical Report No. 42. Lyon, France: IARC; 2005. Available at: Accessed June 3, 2010.
  • 18
    Surveillance, Epidemiology and End Results (SEER) Program. SEER Site Recode ICD-O-3 (1/27/2003) Definition. Available at: Accessed June 3, 2010.
  • 19
    Schneider MF, Gange SJ, Williams CM, et al. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS 2005; 19: 2009-2018.
  • 20
    Surveillance, Epidemiology and End Results (SEER) Program. Limited-Use Data (1973-2007). Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch, released April 2010, based on the November 2009 submission. Available at: Accessed June 3, 2010.
  • 21
    Inskip H. Standardization methods. In: GailMH, BenichouJ, eds. Encyclopedia of Epidemiologic Methods. New York: John Wiley & Sons; 2000: 871-884.
  • 22
    Newman SC. Biostatistical Methods in Epidemiology. New York: John Wiley & Sons; 2001.
  • 23
    Chaturvedi AK, Mbulaiteye SM, Engels EA. Underestimation of relative risks by standardized incidence ratios for AIDS-related cancers. Ann Epidemiol. 2008; 18: 230-234.
  • 24
    Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies Lancet 2008; 372-293-299.
  • 25
    D'Souza G, Wiley DJ, Li X, et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008; 48: 491-499.
  • 26
    Frisch M. On the etiology of anal squamous carcinoma. Dan Med Bull 2002; 49: 194-209.
  • 27
    Palefsky JM, Holly EA, Efirdc JT, et al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 2005; 19: 1407-1414.
  • 28
    Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006; 24: 1383-1388.
  • 29
    Kirk GD, Merlo C, O'Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007; 45: 103-110.
  • 30
    Clifford GM, Rickenbach M, Lise M, et al. Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood 2009; 113: 5737-5742.
  • 31
    Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006; 108: 3786-3791.
  • 32
    Burgi A, Brodine S, Wegner S. et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005; 104: 1505-1511.
  • 33
    Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67.
  • 34
    Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El-Serag HB. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 2005; 100: 56-63.
    Direct Link:
  • 35
    Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 21: 3447-3453.
  • 36
    Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285: 1736-1745.
  • 37
    Mackillop WJ, Zhang-Salomons J, Boyd CJ, Groome PA. Associations between community income and cancer incidence in Canada and the United States. Cancer 2000; 89: 901-912.
  • 38
    Hessol NA, Seaberg EC, Preston-Martin S, et al. Cancer risk among participants in the women's interagency HIV study. J Acquir Immune Defic Syndr 2004; 36: 978-985.
  • 39
    Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 1999; 281: 1822-1829.